Covaxin approved by WHO for emergency use

Finally, WHO's Technical Advisory Group has recommended emergency use listing status for Bharat Biotech's Covaxin, according to sources.

The WHO is in the process of evaluating Covaxin's clinical trial data for use of EUL.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.